. 2016 Feb 16;34:363–391. doi: 10.1007/s40273-015-0348-x

Table 2.

Three-month probabilities of treatment discontinuation (i.e. relapse, switch and interruption)

Items	PLAI	RLAI	ALAI	OLAI	HLAI	OO	Clozapine	Sources
3-month probability of relapse^a
IP	0.0659 [39]	0.0701 [39]	0.0820 [40]	0.0640 [40]	0.1052 [40]	0.0640^d [40]	0.1158^e	RCT for PLAI and RLAI [39], and meta-analysis for other comparators [40]
PP	0.0825^f	0.0825 [26]	0.0825^f	0.0825^f	0.1810 [26]	0.1532 [26]	0.1158 [72]	Observational data for all comparators [26], meta-analysis vs. OO for clozapine [72]
3-month probability of switch^b
IP	0.0329 [39]	0.0163 [39]	0.0413 [40]	0.0320 [40]	0.0537 [40]	0.0320^d	0.0048^e	RCT for PLAI and RLAI [39], and meta-analysis for other comparators [40]
PP	0.0042 [38]	0.0042^g	0.0042^g	0.0042^g	0.0042^g	0.0042^g	0.0048 [72]	RCT for PLAI [38], meta-analysis vs. OO for clozapine [72]
3-month probability of interruption^c
IP	0.1450 [39]	0.1452 [39]	0.1767 [40]	0.1412 [40]	0.2203 [40]	0.1412^d	0.0230^e	RCT for PLAI and RLAI [39], and meta-analysis for other comparators [40]
PP	0.0387 [38]	0.0387^g	0.0387^g	0.0387^g	0.0387^g	0.0387^g	0.0230 [72]	Hough et al. [38] Haro et al. [72]

Formula applied for probabilities derived from OR: $p_{XLAI} = \frac{p_{PLAI} \times (\frac{1}{OR})}{(1 - p_{PLAI}) + (p_{PLAI} \times (\frac{1}{OR}))}$

ALAI aripiprazole long-acting injectable, HLAI haloperidol long-acting injectable, IP Initiation phase, OLAI olanzapine long-acting injectable, OO oral olanzapine, OR odds ratio, PLAI paliperidone long-acting injectable, PP prevention phase, RCT randomised controlled trial, RLAI risperidone long-acting injectable, SmPC summary of product characteristics

^aDue to lack of efficacy

^bDue to lack of tolerance

^cDue to patient choice, loss to follow-up and other reasons

^dAssumed equal to olanzapine LAI

^eProbabilities assumed to be similar for clozapine in initiation and in prevention phase

^fAssumed equal to risperidone LAI

^gAssumed equal to paliperidone LAI